GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » EV-to-EBITDA

Maat Pharma (XPAR:MAAT) EV-to-EBITDA : -5.36 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Maat Pharma's enterprise value is €98.83 Mil. Maat Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.44 Mil. Therefore, Maat Pharma's EV-to-EBITDA for today is -5.36.

The historical rank and industry rank for Maat Pharma's EV-to-EBITDA or its related term are showing as below:

XPAR:MAAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.18   Med: -3   Max: 2.11
Current: -5.35

During the past 6 years, the highest EV-to-EBITDA of Maat Pharma was 2.11. The lowest was -6.18. And the median was -3.00.

XPAR:MAAT's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.42 vs XPAR:MAAT: -5.35

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), Maat Pharma's stock price is €7.86. Maat Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.700. Therefore, Maat Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Maat Pharma EV-to-EBITDA Historical Data

The historical data trend for Maat Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma EV-to-EBITDA Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -27.12 -26.79 -11.02 -4.24 -3.83

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.02 - -4.24 - -3.83

Competitive Comparison of Maat Pharma's EV-to-EBITDA

For the Biotechnology subindustry, Maat Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maat Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Maat Pharma's EV-to-EBITDA falls into.



Maat Pharma EV-to-EBITDA Calculation

Maat Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=98.827/-18.444
=-5.36

Maat Pharma's current Enterprise Value is €98.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maat Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maat Pharma  (XPAR:MAAT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Maat Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.86/-1.700
=At Loss

Maat Pharma's share price for today is €7.86.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maat Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Maat Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Maat Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Maat Pharma (XPAR:MAAT) Business Description

Traded in Other Exchanges
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma (XPAR:MAAT) Headlines

No Headlines